CL04177

CL04177 is a synthetic peptide-based investigational drug developed to selectively eliminate "scarred" senescent and cancer cells, particularly those enriched in phosphorylated p53. It targets the interaction between FOXO4 and p53, disrupting their binding to induce apoptosis specifically in scarred or senescent cells that are resistant to conventional therapies. This mechanism is designed for precision medicine approaches against late-stage cancers such as metastatic colon cancer and triple-negative breast cancer (TNBC), as well as other diseases associated with pathological cellular senescence. Preclinical studies have shown that CL04177 can reduce primary tumor growth and metastatic burden in vivo, with favorable pharmacokinetics, stability, and safety profiles demonstrated in animal models[1][3][4][5].